<html>
<head>PUBMED IDs for TIG3</head>
<body bgcolor='#C5F0F2'><h1>TIG3</h1><a href='https://pubmed.ncbi.nlm.nih.gov/9843971/'>Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene.</a> December 9  1998<br><a href='https://pubmed.ncbi.nlm.nih.gov/10687848/'>Cloning and characterization of a novel retinoid-inducible gene 1(RIG1) deriving from human gastric cancer cells.</a> February 25  2000<br><a href='https://pubmed.ncbi.nlm.nih.gov/10811633/'>Telomerase activity reconstituted in vitro with purified human telomerase reverse transcriptase and human telomerase RNA component.</a> May 16  2000<br><a href='https://pubmed.ncbi.nlm.nih.gov/11078805/'>The carboxy-terminal hydrophobic domain of TIG3, a class II tumor suppressor protein, is required for appropriate cellular localization and optimal biological activity.</a> November 18  2000<br><a href='https://pubmed.ncbi.nlm.nih.gov/12879006/'>Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype.</a> July 25  2003<br><a href='https://pubmed.ncbi.nlm.nih.gov/15455391/'>Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma.</a> September 30  2004<br><a href='https://pubmed.ncbi.nlm.nih.gov/15856468/'>Suppression of the TIG3 tumor suppressor gene in human ovarian carcinomas is mediated via mitogen-activated kinase-dependent and -independent mechanisms.</a> April 28  2005<br><a href='https://pubmed.ncbi.nlm.nih.gov/16306044/'>Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis.</a> November 25  2005<br><a href='https://pubmed.ncbi.nlm.nih.gov/16360957/'>Induction of apoptosis in A549 human lung cancer cells by all-trans retinoic acid incorporated in DOTAP/cholesterol liposomes.</a> December 20  2005<br><a href='https://pubmed.ncbi.nlm.nih.gov/17762858/'>Localization of the TIG3 transglutaminase interaction domain and demonstration that the amino-terminal region is required for TIG3 function as a keratinocyte differentiation regulator.</a> September 1  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/17762857/'>Absence of PDGFRA mutations in primary melanoma.</a> September 1  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/18612777/'>TIG3: a regulator of type I transglutaminase activity in epidermis.</a> July 10  2008<br><a href='https://pubmed.ncbi.nlm.nih.gov/19615464/'>Characterization of the human tumor suppressors TIG3 and HRASLS2 as phospholipid-metabolizing enzymes.</a> January 7  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/19696787/'>p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC.</a> July 14  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/20100577/'>Expression, purification and biochemical characterization of the N-terminal regions of human TIG3 and HRASLS3 proteins.</a> May 13  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/22009441/'>Transglutaminase 1 and its regulator tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies.</a> January 20  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/22616991/'>Expression of the class II tumor suppressor gene RIG1 is directly regulated by p53 tumor suppressor in cancer cell lines.</a> June 26  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/24401997/'>Pericentrosomal localization of the TIG3 tumor suppressor requires an N-terminal hydrophilic region motif.</a> June 18  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/24599174/'>TIG3: an important regulator of keratinocyte proliferation and survival.</a> August 20  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/24599170/'>The severity of internal carotid artery stenosis is associated with the cyclin-dependent kinase inhibitor 2A gene expression.</a> March 31  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/26951515/'>The antitumor effect of TIG3 in liver cancer cells is involved in ERK1/2 inhibition.</a> February 9  2016<br></body></html>
